Elicio Therapeutics

Elicio Therapeutics is a clinical-stage biotechnology company based in the United States that is developing lymph node-targeted immunotherapies to amplify the immune response against solid tumors. The company's proprietary AMP platform is designed to generate robust immune responses by activating and expanding cancer-fighting T cells, with a focus on challenging cancers like pancreatic ductal adenocarcinoma.